In a major milestone for diagnostic oncology and artificial intelligence in medicine, French medical technology firm Median Technologies has officially secured the CE marking for its flagship product, eyonis LCS. The approval, granted under the stringent European Medical Device Regulation (MDR 2017/745), validates the software’s safety and clinical efficacy, clearing the path for its commercial rollout across the European Economic Area (EEA).
The CE marking, issued by the French notified body GMED, classifies eyonis LCS as a Class IIb medical device—a category reserved for high-risk devices that require rigorous clinical evaluation. This regulatory achievement marks a turning point for Median Technologies, positioning the company as a key player in the European effort to revolutionize lung cancer screening protocols.
The Technological Leap: How eyonis LCS Works
At its core, eyonis LCS is an AI-based Software as a Medical Device (SaMD) designed to assist radiologists and clinicians in the complex task of interpreting low-dose computed tomography (LDCT) scans. Lung cancer remains the leading cause of cancer-related mortality globally, largely because it is frequently detected at an advanced, inoperable stage.
The eyonis LCS system is specifically engineered to identify and characterize lung parenchymal nodules. By providing advanced diagnostic insights, the software helps clinicians navigate the often-ambiguous landscape of lung nodule evaluation. It facilitates early diagnosis, refined risk stratification, and data-backed clinical management decisions, effectively acting as a “second pair of eyes” for busy radiology departments.
Chronology: A Path from Innovation to Global Regulatory Approval
The journey toward the CE marking was neither short nor simple, reflecting the high regulatory hurdles mandated by European authorities.
- Development Phase: Median Technologies spent years training its AI models on massive, high-quality datasets to ensure that the software could handle the inherent variability found in clinical lung scans.
- February 2026: The company achieved its first major regulatory victory when the US Food and Drug Administration (FDA) cleared eyonis LCS for use in the United States. This served as a crucial proof-of-concept, establishing the software’s clinical validity in a highly regulated market.
- The MDR Transition: Following the US success, Median shifted its focus to the European market. Navigating the EU’s Medical Device Regulation (MDR) requires a significantly higher threshold for clinical evidence compared to previous directives.
- July 2026: The French notified body GMED officially awarded the CE mark, confirming that eyonis LCS complies with the rigorous safety and performance standards required for Class IIb devices.
This dual-approval status in the US and the EU represents a strategic global expansion, allowing Median Technologies to target major hospital networks and lung cancer screening programs on both sides of the Atlantic.
Clinical Performance: Data-Driven Superiority
The primary challenge in lung cancer screening today is the high rate of diagnostic error. Traditional screening is often plagued by false positives, which lead to unnecessary, invasive biopsies and patient anxiety, as well as false negatives, which allow tumors to grow undetected.
Median Technologies has released internal data that suggests eyonis LCS significantly outperforms standard radiologist-led screening. According to the company:
- Sensitivity: The software demonstrates a 93.3% sensitivity rate, compared to the 80.3% reported for standard radiologist assessments. This indicates that the AI is significantly better at detecting the presence of cancerous nodules.
- Specificity: The device reports a 92.4% specificity rate, compared to the 76.4% found in traditional screening. High specificity is crucial, as it drastically reduces the number of false alarms, sparing patients from unnecessary follow-up procedures.
By combining computer-aided detection (CADe) and computer-aided diagnosis (CADx) within a single workflow, eyonis LCS offers a unified solution that streamlines the entire screening pathway, from initial identification to final risk assessment.
Official Perspectives: A Vision for the Future of Oncology
Fredrik Brag, founder and CEO of Median Technologies, has framed the CE marking as a critical milestone in the company’s mission to democratize access to life-saving diagnostics.
"Receiving CE marking is a critical step in our mission to make earlier, more accurate lung cancer diagnosis accessible to more patients eligible for lung cancer screening in Europe," Brag stated following the announcement. "Several European nations have already launched lung cancer screening programs. Our AI-based eyonis LCS SaMD was developed specifically to aid in the earlier detection and diagnosis of lung cancer, when treatment is more likely to be successful, helping patients gain faster access to potentially life-saving therapies."
Industry analysts observe that Brag’s focus on national screening programs is key. As European countries increasingly adopt government-led lung cancer screening initiatives—mirroring the successful models of breast and cervical cancer screening—the demand for automated, high-precision diagnostic tools is expected to surge.
Implications for Healthcare Systems and Patients
The integration of AI into radiology workflows is no longer a futuristic concept; it is an economic and clinical necessity. The implications of this CE marking are far-reaching:
1. Reducing the Radiologist Burden
Radiologists are currently facing unprecedented volumes of imaging data. AI tools like eyonis LCS do not replace the clinician but rather augment their capabilities, allowing them to focus their expertise on the most complex cases while the AI handles routine screening tasks with high consistency.
2. Improving Resource Allocation
By reducing the rate of false positives, healthcare systems can save millions of euros annually. Unnecessary PET scans, biopsies, and surgical interventions are not only costly but also carry physical risks for patients. By ensuring that only high-risk nodules are escalated for further intervention, eyonis LCS optimizes the use of hospital resources.
3. Patient Outcomes and Quality of Life
The ultimate measure of success for any diagnostic tool is patient survival. If eyonis LCS can shift the average stage of diagnosis from Stage IV to Stage I or II, the survival rates for lung cancer patients will climb dramatically. Earlier intervention means less aggressive treatments, faster recovery times, and significantly higher five-year survival probabilities.
The Competitive Landscape of AI Diagnostics
While many companies are vying for space in the AI-medical imaging market, Median Technologies distinguishes itself by integrating its solution directly into the LDCT screening pathway. Unlike standalone diagnostic apps that might function as separate, isolated tools, eyonis LCS is designed to be a holistic component of the patient’s clinical journey.
The software is also a beneficiary of the "MDR era." By meeting the strict requirements of the European MDR, Median Technologies has secured a "moat" around its product. Smaller, less established competitors may struggle to meet these regulatory requirements, potentially leaving the market open for companies like Median to establish dominant positions in major European healthcare markets.
Looking Ahead: The Future of Lung Screening
As Median Technologies begins its commercial rollout, the industry will be watching closely to see how effectively the software is adopted by European hospital trusts and diagnostic centers. The success of eyonis LCS will likely serve as a blueprint for other AI-based medical devices seeking regulatory approval.
Furthermore, the company is expected to continue refining its algorithms. As more data is processed through the eyonis platform, the potential for machine learning to improve the system’s sensitivity and specificity remains high. The company’s focus on integrating computer-aided detection and diagnosis represents a holistic approach that sets a new industry standard.
In conclusion, the CE marking for eyonis LCS is more than a regulatory box-ticking exercise; it is a validation of the potential for artificial intelligence to solve one of the most stubborn problems in oncology. By combining rigorous clinical validation with cutting-edge software architecture, Median Technologies is poised to play a central role in the next generation of lung cancer diagnostics, offering new hope to millions of patients across Europe.
About the Author
